MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.preghy.2026.101455

Медицинская библиотека · Pregnancy hypertension · 2026

Prediction of severe maternal and perinatal complications in hypertensive pregnancies using point-of-care glycosylated fibronectin: A prospective cohort study.

Martin Anastasia, Kuhrt Katy, Tamba M'Bayoh Moses, Cole Rossetta, Hurrell Alice, Seed Paul T, Bramham Kate, Shennan Andrew

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

OBJECTIVES

To evaluate the test accuracy of glycosylated fibronectin (GlyFn) to predict adverse maternal and neonatal outcomes in women with hypertensive pregnancies in a low resourced setting.

STUDY

DESIGN

Prospective observational study at a Tertiary government hospital in Freetown, Sierra Leone. Hypertensive women between 24 - 36 + 6 weeks' gestation were recruited and Point-of-care GlyFn test was performed at time of recruitment.

MAIN OUTCOME MEASURES: Diagnostic accuracy measures for adverse maternal (maternal death and eclampsia) and neonatal (stillbirth, neonatal death and termination pre-viability) outcomes including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), were calculated for predefined GlyFn thresholds using STATA.

RESULTS

Complete outcome data was available for 172 women. 11.6% (20/172) of women had a composite maternal outcome with 16 cases of eclampsia and eight maternal deaths. For the composite maternal outcome and stillbirth, GlyFn had a 100% sensitivity and NPV when taken before 34 weeks' gestation. GlyFn also showed good time to delivery prediction when taken before 34 week gestation (AUROC: 0.69, [0.56 - 0.81]) and good predictive performance for placental abruption (AUROC: 0.82, [0.75-0.88]) and small-for-gestational-age babies (below the 3rd centile) (AUROC: 0.71, [0.54-0.87]).

CONCLUSIONS

In low-resource settings, GlyFn could serve as a risk-stratification tool for severe maternal and neonatal complications in women presenting with hypertension in low-resource settings.

Для цитирования: Martin Anastasia, Kuhrt Katy, Tamba M'Bayoh Moses, Cole Rossetta, Hurrell Alice, Seed Paul T, Bramham Kate, Shennan Andrew. Prediction of severe maternal and perinatal complications in hypertensive pregnancies using point-of-care glycosylated fibronectin: A prospective cohort study.. Pregnancy hypertension. 2026. DOI: 10.1016/j.preghy.2026.101455.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.